Helen Torley - Feb 7, 2023 Form 4 Insider Report for HALOZYME THERAPEUTICS, INC. (HALO)

Role
PRESIDENT AND CEO, Director
Signature
/s/ James R. Oehler, Attorney-in-Fact
Stock symbol
HALO
Transactions as of
Feb 7, 2023
Transactions value $
-$1,530,150
Form type
4
Date filed
2/9/2023, 04:44 PM
Previous filing
Jan 19, 2023
Next filing
Feb 14, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction HALO Common Stock Options Exercise $147K +10K +1.7% $14.66 597K Feb 7, 2023 Direct F1
transaction HALO Common Stock Sale -$513K -10K -1.67% $51.26 587K Feb 7, 2023 Direct F1, F2
transaction HALO Common Stock Options Exercise $147K +10K +1.7% $14.66 597K Feb 8, 2023 Direct F1
transaction HALO Common Stock Sale -$514K -10K -1.67% $51.36 587K Feb 8, 2023 Direct F1, F3
transaction HALO Common Stock Options Exercise $147K +10K +1.7% $14.66 597K Feb 9, 2023 Direct F1
transaction HALO Common Stock Sale -$504K -10K -1.67% $50.40 587K Feb 9, 2023 Direct F1, F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction HALO Option to Purchase Common Stock Options Exercise -$147K -10K -16.67% $14.66 50K Feb 7, 2023 Common Stock 10K $14.66 Direct F1, F5
transaction HALO Option to Purchase Common Stock Options Exercise -$147K -10K -20% $14.66 40K Feb 8, 2023 Common Stock 10K $14.66 Direct F1, F5
transaction HALO Option to Purchase Common Stock Options Exercise -$147K -10K -25% $14.66 30K Feb 9, 2023 Common Stock 10K $14.66 Direct F1, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on September 7, 2022 in accordance with Rule 10b5-1.
F2 Represents a weighted average sales price per share. The shares were sold at prices ranging from $51.08 to $51.85. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F3 Represents a weighted average sales price per share. The shares were sold at prices ranging from $51.13 to $51.58. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F4 Represents a weighted average sales price per share. The shares were sold at prices ranging from $50.22 to $50.555. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F5 Grant to Reporting Person of options, exercisable over a 4-year period measured from the date of grant, 25% after 12 months, then 1/48th of the Option Shares per month thereafter. The date of grant was January 6, 2014.